価格表

在庫・価格 : 2024年04月30日 01時55分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-HRAS, Rabbit-Poly
データシート
GTX116041 GNTジーンテックス
GeneTex International Corporation
100 μl ¥75,000 1個 追加

在庫・価格 : 2024年04月30日 01時55分 現在

Anti-HRAS, Rabbit-Poly

  • 商品コード:GTX116041
  • メーカー:GNT
  • 包装:100μl
  • 価格: ¥75,000
  • 在庫:1個
使用文献
No. 文献情報 備考 参照
1 Tsuboi M et al. The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells. J. Biol. Chem. 2017 10;292(43):17681-17702
Tsuboi M et al
2017/01/01
Application: Western Blot (WB), Reactivity: Human PubMed
2 Brandt LP et al. Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. PLoS ONE 2017;12(10):e0186102
Brandt LP et al
2017/01/01
Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Mouse PubMed
3 Sarin N et al. Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach. Int J Mol Sci 2018 Mar;19(3)
Sarin N et al
2018/01/01
Application: Western Blot (WB), Reactivity: Human PubMed
4 Sugita S et al. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. Int. J. Oncol. 2018 Aug;53(2):725-736
Sugita S et al
2018/01/01
, Reactivity: Human PubMed
5 Gao P et al. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Breast Cancer Res. 2018 Sep;20(1):112
Gao P et al
2018/01/01
Application: Immunoprecipitation, Reactivity: Human PubMed
6 Brandt LP et al. Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget 2018 Apr;9(28):19753-19766
Brandt LP et al
2018/01/01
PubMed
7 Hu W et al. NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma. JCI Insight 2021 02;6(3)
Hu W et al
2021/01/01
PubMed
8 Wu HT et al. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. Am J Chin Med 2020;48(5):1221-1241
Wu HT et al
2020/01/01
PubMed
9 Catalano A et al. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers (Basel) 2021 Apr;13(8)
Catalano A et al
2021/01/01
PubMed
  • No.: 1
  • 文献情報:
    Tsuboi M et al. The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells. J. Biol. Chem. 2017 10;292(43):17681-17702
    Tsuboi M et al
    2017/01/01
  • 備考:
    Application: Western Blot (WB), Reactivity: Human
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Brandt LP et al. Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. PLoS ONE 2017;12(10):e0186102
    Brandt LP et al
    2017/01/01
  • 備考:
    Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Mouse
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Sarin N et al. Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach. Int J Mol Sci 2018 Mar;19(3)
    Sarin N et al
    2018/01/01
  • 備考:
    Application: Western Blot (WB), Reactivity: Human
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Sugita S et al. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. Int. J. Oncol. 2018 Aug;53(2):725-736
    Sugita S et al
    2018/01/01
  • 備考:
    , Reactivity: Human
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Gao P et al. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Breast Cancer Res. 2018 Sep;20(1):112
    Gao P et al
    2018/01/01
  • 備考:
    Application: Immunoprecipitation, Reactivity: Human
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Brandt LP et al. Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget 2018 Apr;9(28):19753-19766
    Brandt LP et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Hu W et al. NOGOB receptor-mediated RAS signaling pathway is a target for suppressing proliferating hemangioma. JCI Insight 2021 02;6(3)
    Hu W et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Wu HT et al. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. Am J Chin Med 2020;48(5):1221-1241
    Wu HT et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Catalano A et al. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers (Basel) 2021 Apr;13(8)
    Catalano A et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed